Unraveling the Role of PCDH9 in Breast Cancer and Identifying Therapeutic Strategies for PCDH9-Deficient Tumors

Overview

Journal Breast Cancer (Dove Med Press)

Publisher Dove Medical Press

Date 2024 Sep 16

PMID 39279908

Authors

Ruixi Li

Lulu Liu

Yong Liu

Jiang Tang

JinSong Li

Affiliations

Soon will be listed here.

Abstract

Introduction: Protocadherin 9 (PCDH9), a member of the cadherin superfamily of transmembrane proteins, plays a role in cell adhesion and neural development. Recent studies suggest that PCDH9 may function as a tumor suppressor in certain cancers, though its specific role in breast cancer remains unclear.

Methods: UALCAN database to retrieve information on PCDH9 expression in breast cancer tissues compared with that in normal tissues. The biological effects of PCDH9 in breast cancer cells were analyzed using the DepMap database. Stable knockdown or overexpression of PCDH9 in breast cancer cell lines and subsequently assessed tumor cell proliferation and migration. Synthetic lethal screening was conducted for breast cancer cells with low PCDH9 expression or deficiency.

Results: In this study, we observed significant downregulation of PCDH9 in breast cancer tissues, with its expression negatively correlated with progression-free survival. Further investigations revealed that decreased PCDH9 expression promotes breast cancer cell proliferation and migration, while overexpression of PCDH9 has the opposite effect. Subsequently, we identified the TAS-102, an approved drug for metastatic colorectal cancer, exhibited selective cytotoxicity against breast cancer cells with low PCDH9 expression.

Conclusion And Discussion: In summary, our study identified PCDH9 as a tumor suppressor in breast cancer and highlighted TAS-102 as a potential therapeutic option for tumors with low PCDH9 expression or deficiency. The specific interaction between TAS-102 and PCDH9 warrants further exploration, providing deeper insights into its mode of action in treating PCDH9-deficient breast cancer.

References

Pancho A, Aerts T, Mitsogiannis M, Seuntjens E . Protocadherins at the Crossroad of Signaling Pathways. Front Mol Neurosci. 2020; 13:117. PMC: 7339444. DOI: 10.3389/fnmol.2020.00117. View

Zonneville J, Wang M, Alruwaili M, Smith B, Melnick M, Eng K . Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. Commun Biol. 2021; 4(1):862. PMC: 8275734. DOI: 10.1038/s42003-021-02370-0. View

Clusan L, Ferriere F, Flouriot G, Pakdel F . A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int J Mol Sci. 2023; 24(7). PMC: 10095386. DOI: 10.3390/ijms24076834. View

Guo L, Kong D, Liu J, Zhan L, Luo L, Zheng W . Breast cancer heterogeneity and its implication in personalized precision therapy. Exp Hematol Oncol. 2023; 12(1):3. PMC: 9830930. DOI: 10.1186/s40164-022-00363-1. View

Campbell I, Russell S, Choong D, Montgomery K, Ciavarella M, Hooi C . Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004; 64(21):7678-81. DOI: 10.1158/0008-5472.CAN-04-2933. View

Lv J, Zhu P, Zhang X, Zhang L, Chen X, Lu F . PCDH9 acts as a tumor suppressor inducing tumor cell arrest at G0/G1 phase and is frequently methylated in hepatocellular carcinoma. Mol Med Rep. 2017; 16(4):4475-4482. PMC: 5647006. DOI: 10.3892/mmr.2017.7193. View

Giaquinto A, Sung H, Miller K, Kramer J, Newman L, Minihan A . Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022; 72(6):524-541. DOI: 10.3322/caac.21754. View

Conti M, Bolzacchini E, Luchena G, Bertu L, Tagliabue P, Aglione S . Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study. Cancers (Basel). 2023; 15(13). PMC: 10340604. DOI: 10.3390/cancers15133465. View

Lenz H, Stintzing S, Loupakis F . TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat Rev. 2015; 41(9):777-83. PMC: 4624296. DOI: 10.1016/j.ctrv.2015.06.001. View

10.

Vaz E, Vassiliades S, Giarolla J, Polli M, Parise-Filho R . Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. Eur J Clin Pharmacol. 2023; 79(6):723-751. PMC: 10118228. DOI: 10.1007/s00228-023-03486-4. View

11.

Lamb C, Vanzulli S, Lanari C . Hormone receptors in breast cancer: more than estrogen receptors. Medicina (B Aires). 2019; 79(Spec 6/1):540-545. View

12.

Chandrashekar D, Karthikeyan S, Korla P, Patel H, Shovon A, Athar M . UALCAN: An update to the integrated cancer data analysis platform. Neoplasia. 2022; 25:18-27. PMC: 8788199. DOI: 10.1016/j.neo.2022.01.001. View

13.

Swain S, Shastry M, Hamilton E . Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2022; 22(2):101-126. PMC: 9640784. DOI: 10.1038/s41573-022-00579-0. View

14.

Rofaiel S, Muo E, Mousa S . Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management. Pharmgenomics Pers Med. 2012; 3:129-43. PMC: 3513214. DOI: 10.2147/PGPM.S10789. View

15.

Hassin O, Oren M . Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov. 2022; 22(2):127-144. PMC: 9549847. DOI: 10.1038/s41573-022-00571-8. View

16.

Zhu P, Lv J, Yang Z, Guo L, Zhang L, Li M . Protocadherin 9 inhibits epithelial-mesenchymal transition and cell migration through activating GSK-3β in hepatocellular carcinoma. Biochem Biophys Res Commun. 2014; 452(3):567-74. DOI: 10.1016/j.bbrc.2014.08.101. View

17.

Takeichi M . The cadherin superfamily in neuronal connections and interactions. Nat Rev Neurosci. 2006; 8(1):11-20. DOI: 10.1038/nrn2043. View

18.

Weng J, Xiao J, Mi Y, Fang X, Sun Y, Li S . PCDHGA9 acts as a tumor suppressor to induce tumor cell apoptosis and autophagy and inhibit the EMT process in human gastric cancer. Cell Death Dis. 2018; 9(2):27. PMC: 5833845. DOI: 10.1038/s41419-017-0189-y. View

19.

Haruki S, Imoto I, Kozaki K, Matsui T, Kawachi H, Komatsu S . Frequent silencing of protocadherin 17, a candidate tumour suppressor for esophageal squamous cell carcinoma. Carcinogenesis. 2010; 31(6):1027-36. DOI: 10.1093/carcin/bgq053. View

20.

Kuchenbaecker K, Hopper J, Barnes D, Phillips K, Mooij T, Roos-Blom M . Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017; 317(23):2402-2416. DOI: 10.1001/jama.2017.7112. View